Evidence map›Paper›PMID 33708957›Full record

ArticleAnnals of translational medicine2021

A systematic analysis of a potential metabolism-related prognostic signature for breast cancer patients.

Shibo Yu, Xiaowen Wang, Lizhe Zhu, Peiling Xie, Yudong Zhou, Siyuan Jiang, Heyan Chen, Xiaoqin Liao, Shengyu Pu, Zhenzhen Lei and 2 more

Abstract read
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Silencing RPL9 promotes malignant proliferation in breast cancer cells.International journal of immunopathology and pharmacology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shibo YuDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xiaowen WangDepartment of Second Breast surgery, the Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.
Lizhe ZhuDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Peiling XieDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yudong ZhouDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Siyuan JiangDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Heyan ChenDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xiaoqin LiaoDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Shengyu PuDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zhenzhen LeiDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Bin WangDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yu RenDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic pathways play an essential role in breast cancer. However, the role of metabolism-related genes in the early diagnosis of breast cancer remains unknown.

methodsIn our study, RNA sequencing (RNA-seq) expression data and clinicopathological information from The Cancer Genome Atlas (TCGA) and GSE20685 were obtained. Univariate cox regression and least absolute shrinkage and selection operator (LASSO) regression analyses were performed on the differentially expressed metabolism-related genes. Then, the formula of the metabolism-related risk model was composed, and the risk score of each patient was calculated. The breast cancer patients were divided into high-risk and low-risk groups with a cutoff of the median expression value of the risk score, and the prognostic analysis was also used to analyze the survival time between these two groups. In the end, we also analyzed the expression, interaction, and correlation among genes in the metabolism-related gene risk model.

resultsThe results from the prognostic analysis indicated that the survival was significantly poorer in the high-risk group than in the low-risk group in both TCGA and GSE20685 datasets. In addition, after adjusting for different clinicopathological features in multivariate analysis, the metabolism-related risk model remained an independent prognostic indicator in TCGA dataset.

conclusionsIn summary, we systematically developed a potential metabolism-related gene risk model for predicting prognosis in breast cancer patients.

Indexed as

Breast cancerGene Expression Omnibus (GEO)metabolismprognostic signatureThe Cancer Genome Atlas (TCGA)

Identifiers

PMID33708957
PMCPMC7944328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.